Form 4: Kiora Pharmaceuticals Director Hollander Acquires Stock Options

Director David Hollander receives options to purchase 20,000 shares of Kiora Pharmaceuticals stock, exercisable starting April 1, 2026.

Summary

• David Hollander, a director of Kiora Pharmaceuticals, received options to purchase 20,000 shares of the company's common stock on April 1, 2025.
• The options were granted pursuant to the Issuer's 2024 Equity Incentive Plan.
• The exercise price of the options is $2.93 per share.
• The options become fully exercisable on April 1, 2026, and expire on April 1, 2035.
• Following the transaction, Hollander directly owns 20,000 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The granting of options can be seen as a positive sign of aligning management interests with shareholders, but it's a standard practice.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with shareholders.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, Kiora Pharmaceuticals, equity incentive plan, beneficial ownership, Form 4